Menu

GAO restated its controversial 2015 finding that 340B covered entities prescribe more drugs or more expensive drugs than necessary.

Government Watchdog Reissues Controversial Finding on Adverse Incentives in 340B Program

August 8, 2023 William Newton, Editor-in-Chief 340B Report Views

The U.S. Government Accountability Office late last month restated its controversial recommendation that Congress take actions to reduce incentives for [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.

Please be sure you’ve completed your one-minute subscription completion form.
I have read and accepted the terms of use and privacy policy.
Log In!

If you are not yet a paid subscriber, please Subscribe now

For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

William Newton

Hospitals Charge Average 500% of Top 20 Drug Costs, Says PhRMA-Funded Analysis

Making the Case for Your 340B Program